FDA approves new medication for schizophrenia that may be alternative to Zyprexa
Individuals who buy Zyprexa to treat schizophrenia may soon have another option available in the form of INVEGA extended-release tablets, a product that was recently approved by the U.S. Food and Drug Administration.
Individuals who buy Zyprexa to treat schizophrenia may soon have another option available in the form of INVEGA extended-release tablets, a product that was recently approved by the U.S. Food and Drug Administration. This medication was especially recommended for adolescents between the ages of 12 and 17 who suffer from symptoms such as hearing voices, delusions, disorganized thinking or other unusual behaviors.
According to doctors, early diagnosis and prompt treatment are critical in managing this lifelong disease, for which there is currently no known cure.
"Although rare, schizophrenia in adolescents is a very serious and disabling brain condition that affects every aspect of an adolescent's life and has significant consequences," said Husseini Manji, an expert at Johnson and Johnson Pharmaceutical Research and Development. "This new indication for INVEGA provides an additional option for clinicians who treat adolescents with schizophrenia."
A six-week trial conducted among young adults in several countries has ensured the safety and efficacy of this remedy.
As a result, many doctors could soon be recommending this product to schizophrenic patients, including those who currently buy Zyprexa.
|
